Korean Regulatory Overhaul To Cut R&D, Approval Periods
This article was originally published in PharmAsia News
Executive Summary
In its latest series of broad support measures for the biopharma sector, South Korea is to ease selected regulatory rules to shorten R&D and approval periods, and ensure the prompt and stable supply of drugs essential for public health.